Vancomycin Reduction Practices (VRP) in the NICU

Launched by CHILDREN'S HOSPITAL OF PHILADELPHIA · Jan 9, 2025

Keywords

ClinConnect Summary

The Vancomycin Reduction Practices (VRP) trial is a study aimed at improving how hospitals reduce the use of a specific antibiotic called vancomycin in neonatal intensive care units (NICUs). This trial will look at different ways to encourage hospitals to follow best practices for using vancomycin, particularly for newborns with late-onset sepsis, which is an infection that occurs in babies after the first week of life. Hospitals will be divided into two groups: one will receive extra support and guidance from the study team, while the other will not. Both groups will have access to tools and training to help staff improve their antibiotic use.

To be part of this study, hospitals need to be a Level III NICU, which means they provide advanced care for critically ill newborns. They must also be part of specific networks, like Kaiser Permanente Northern California or the Children's Hospital of Philadelphia Newborn Care Network. The trial is not yet recruiting participants, but once it starts, hospitals will be expected to engage in training and feedback sessions aimed at improving their antibiotic practices. This study is important because it seeks to ensure that babies receive the safest and most effective treatment while minimizing unnecessary antibiotic use.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Level III NICU
• • Affiliated with Kaiser Permanente Northern California (KPNC) or Children's Hospital of Philadelphia Newborn Care Network (CNBCN)
• • Recruited by study team
• Exclusion Criteria:
• • Site not recruited for the study